did-you-know? rent-now

Amazon no longer offers textbook rentals. We do!

did-you-know? rent-now

Amazon no longer offers textbook rentals. We do!

We're the #1 textbook rental company. Let us show you why.

9781573312912

The Camptothecins: Unfolding Their Anticancer Potential

by ; ;
  • ISBN13:

    9781573312912

  • ISBN10:

    1573312916

  • Edition: 1st
  • Format: Hardcover
  • Copyright: 2000-12-01
  • Publisher: New York Academy of Sciences
  • Purchase Benefits
  • Free Shipping Icon Free Shipping On Orders Over $35!
    Your order must be $35 or more to qualify for free economy shipping. Bulk sales, PO's, Marketplace items, eBooks and apparel do not qualify for this offer.
  • eCampus.com Logo Get Rewarded for Ordering Your Textbooks! Enroll Now
  • Write a Review Icon Write a Review
List Price: $140.00

Table of Contents

Introduction xi
Joachim G. Liehr
Beppino Giovanella
Keynote Lecture
Mechanism of Action of Camptothecin.
1(10)
Leroy F. Liu
Shyamal D. Desai
Tsai-Kun Li
Yong Mao
Mei Sun
Sai-Peng Sim
Part I. Mechanism of Action of Camptothecins
Molecular and Biological Determinants of the Cytotoxic Actions of Camptothecins. Perspective for the Development of New Topoisomerase I Inhibitors.
11(16)
Kurt W. Kohn
Yves Pommier
Dependence of Anticancer Activity of Camptothecins on Maintaining Their Lactone Function.
27(9)
B.C. Giovanella
N. Harris
J. Mendoza
Z. Cao
J. Liehr
J.S. Stehlin
Camptothecin Design and Delivery Approaches for Elevating Anti-Topoisomerase I Activities in Vivo.
36(10)
Thomas G. Burke
David Bom
Mechanisms of Resistance to Camptothecins.
46(10)
Ahamed Saleem
Troy K. Edwards
Zeshaan Rasheed
Eric H. Rubin
Part II. Mechanism-Based Design and Synthesis of Novel Camptothecins
Structure-Based Analysis of the Effects of Camptothecin on the Activities of Human Topoisomerase I.
56(9)
James J. Champoux
Mechanisms of DNA Topoisomerase I-Induced Cell Killing in the Yeast Saccharomyces cerevisiae.
65(11)
Paola Fiorani
Mary-Ann Bjornsti
Camptothecins as Probes of the Microenvironments of Topoisomerase I - DNA Complexes.
76(16)
Sidney M. Hecht
Part III. Novel Topoisomerase I Inhibitors
Preclinical and Clinical Trials of Topoisomerase Inhibitors.
92(8)
Nagahiro Saijo
Homocamptothecins: E-Ring Modified CPT Analogues.
100(12)
Olivier Lavergne
Daniele Demarquay
Philip G. Kasprzyk
Dennis C.H. Bigg
The Cascade Radical Annulation Approach to New Analogues of Camptothecins. Combinatorial Synthesis of Silatecans and Homosilatecans.
112(10)
Dennis P. Curran
Hubert Josien
David Bom
Ana E. Gabarda
Wu Du
Part IV. New Camptothecin Derivatives and Formulations
Structure-Activity Relationship of Alky1 Camptothecin Esters.
122(14)
Zhisong Cao
Panayotis Pantazis
John Mendoza
Janet Early
Anthony Kozielski
Nick Harris
Dana Vardeman
Joachim Liehr
John S. Stehlin
Beppino Giovanella
Conjugation of Camptothecins to Poly-(L-Glutamic Acid).
136(15)
Jack W. Singer
Peter de Vries
Rama Bhatt
John Tulinsky
Peter Klein
Chun Li
Luka Milas
Robert A. Lewis
Sidney Wallace
9-Nitrocamptothecin Liposome Aerosol Treatment of Human Cancer Subcutaneous Xenografts and Pulmonary Cancer Metastases in Mice.
151(13)
Vernon Knight
Eugenie S. Kleinerman
J. Clifford Waldrep
Beppino C. Giovanella
Brian E. Gilbert
Nadezhda V. Koshkina
Modified Lactone/Carboxylate Salt Equilibria in Vivo by Liposomal Delivery of 9-Nitro-Camptothecin.
164(11)
Diana S-L. Chow
Ling Gong
Michael D. Wolfe
Beppino C. Giovanella
New Analogues of Camptothecins. Activity and Resistance.
175(3)
Epie Boven
Annemarie H. Van Hattum
Ilse Hoogsteen
Hennie M.M. Schluper
H.M. Pinedo
Intraperitoneal Topoisomerase-I Inhibitors. Preliminary Findings with 9-Aminocamptothecin.
178(10)
Franco Muggia
Leonard Liebes
Milan Potmesil
Anne Hamilton
Howard Hochster
Gila Hornreich
Joan Sorich
Andrea Downey
Heather Wasserstrom
Part V. Pharmacology
Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance Protein. Potential Clinical Implications.
188(7)
Jan H.M. Schellens
Marc Maliepaard
Rik J. Scheper
George L. Scheffer
Johan W. Jonker
Johan W. Smit
Jos H. Beijnen
Alfred H. Schinkel
Pharmacokinetics of Orally Administered Camptothecins.
195(10)
Elora Gupta
Viral Vyas
Farheena Ahmed
Patrick Sinko
Thomas Cook
Eric Rubin
Metabolism of CPT-11. Impact on Activity.
205(11)
Laurent P. Rivory
Pharmacology of Camptothecin Esters.
216(8)
Joachim G. Liehr
Nick J. Harris
John Mendoza
Ahmed E. Ahmed
Beppino C. Giovanella
Part VI. Clinical Trials I, Newer Analogues
The Clinical Development of 9-Aminocamptothecin.
224(13)
Chris H. Takimoto
Rebecca Thomas
Alternative Administration of Camptothecin Analogues.
237(10)
C.F. Verschraegen
K. Jaeckle
B. Giovanella
V. Knight
B.E. Gilbert
Topotecan (Hycamptin) and Topotecan-Containing Regimens in the Treatment of Hematologic Malignancies.
247(13)
Miloslav Beran
Hagop M. Kantarjian
DX-895 1f: Summary of Phase I Clinical Trials.
260(14)
R. De Jager
P. Cheverton
K. Tamanoi
J. Coyle
M. Ducharme
N. Sakamoto
M. Satomi
M. Suzuki
Part VII. Clinical Trials II, Combination Therapy
Cellular and Molecular Responses to Topoisomerase I Poisons. Exploiting Synergy for Improved Radiotherapy.
274(19)
Shigeki Miyamoto
Tony T. Huang
Shelly Wuerzberger-Davis
William G. Bornmann
John J. Pink
Colleen Tagliarino
Timothy J. Kinsella
David A. Boothman
In Vitro Antitumor Activity of 9-Nitro-Camptothecin as a Single Agent and in Combination with other Antitumor Drugs.
293(5)
Ralph J. Bernacki
Paula Pera
Peter Gambacorta
Yseult Brun
William R. Greco
p53 and p21 Are Major Cellular Determinants for DNA Topoisomerase I-Mediated Radiation Sensitization in Mammalian Cells.
298(3)
Allan Y. Chen
Paul B. Scruggs
Ling Geng
Mace L. Rothenberg
Dennis E. Hallahan
Part VIII. Poster Papers
The Homocamptothecin, BN 80927, Is a Potent Topoisomerase I Poison and Topoisomerase II Catalytic Inhibitor 1.
301(2)
Daniele Demarquay
Helene Coulomb
Marion Huchet
Laurence Lesueur-Ginot
Jose Camara
Olivier Lavergne
Dennis Bigg
The Dual Topoisomerase Inhibitor, BN 80927, Is Highly Potent against Cell Proliferation and Tumor Growth.
303(3)
Marion Huchet
Daniele Demarquay
Helene Coulomb
Philip Kasprzyk
Mark Carlson
Jeffrey Lauer
Olivier Lavergne
Dennis Bigg
Ubiquitin, Sumo-1, and UCRP in Camptothecin Sensitivity and Resistance.
306(3)
Shyamal D. Desai
Yong Mao
Mei Sun
Tsai-Kun Li
Jiaxi Wu
Leroy F. Liu
A Spectrophotometric Study of the pH-Dependent and DNA Binding Properties of Topotecan.
309(5)
Steven E. Miller
Daniel S. Pilch
Kinetics of in Vitro Hydrolysis of Homocamptothecins As Measured by Fluorescence.
314(3)
D. Chauvier
I. Chourpa
D.C.H. Bigg
M. Manfait
The Combinatorial Synthesis of Racemic Homosilatecan Libraries via a Cascade Radical Annulation.
317(3)
Wu Du
Ana E. Gabarda
David Bom
Dennis P. Curran
Combined Radiation and 9-Nitrocamptothecin (Rubitecan) in the Treatment of Locally Advanced Pancreatic Cancer.
320(4)
K.R. Kemp
J.G. Liehr
B. Giovanella
Preclinical and Phase I Clinical Studies with Ckd-602, a Novel Camptothecin Derivative.
324(2)
J.H. Lee
J.M. Lee
K.H. Lim
J.K. Kim
S.K. Ahn
Y.J. Bang
C.I. Hong
Action of Topoisomerase Targeting Drugs on Non-Hodgkin's Lymphoma and Leukemia. Correlation of Clinical and Cell Culture Studies.
326(4)
J.S. Nair
R. Kancherla
K. Seiter
F. Traganos
Y.-C. Tse-Dinh
Improvement of Therapeutic Index of Low-Dose Topotecan Delivered per os.
330(4)
Graziella Pratesi
Michelandrea De Cesare
Franco Zunino
Camptothecin Dose, Schedule, and Timing of Administration for Clinical Radiation Sensitization.
334(6)
Tyvin A. Rich
Alexander V. Kirichenko
Rapid Chromatin Reorganization Induced by Topoisomerase I-Mediated DNA Damage.
340(3)
Mei Sun
Pu Duann
Chin-Tai Lin
Hui Zhang
Leroy F. Liu
NF-B Activation in Topoisomerase I Inhibitor-Induced Apoptotic Cell Death in Human Non-Small Cell Lung Cancer.
343(2)
Masahiro Tabata
Ram Ganapathi
Phase I Study of 9-Nitro-20(S)-Camptothecin in Combination with Cisplatin for Patients with Advanced Malignancies.
345(4)
C.F. Verschraegen
M. Vincent
J.L. Abbruzzese
D. Siegler
J.J. Kavanagh
E. Loyer
A.P. Kudelka
E. Rubin
Phase II Study of Intravenous DX-8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan.
349(3)
C.F. Verschraegen
C. Levenback
M. Vincent
J. Wolf
M. Bevers
E. Loyer
A.P. Kudelka
J.J. Kavanagh
Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Malignancies in the Lungs.
352(3)
C.F. Verschraegen
B.E. Gilbert
A.J. Huaringa
R. Newman
N. Harris
F.J. Leyva
L. Keus
K. Campbell
T. Nelson-Taylor
V. Knight
Inhibition of DNA Replication in Camptothecin-Treated Cells Is Regulated by Protein Kinases.
355(5)
Xiang-Yang Zhou
Ya Wang
Part IX. Concluding Remarks
Concluding Remarks.
360(1)
Claire Verschraegen
Index of Contributors 361

Supplemental Materials

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

Rewards Program